FYI - I am long but CYDY will definitely market share away for sure but to think they won't generate revenue and we take those 2 indications away is pretty hopeful, IMO. Definitely not a zero sum game and I wouldn't be surprised there are folks still buying the 'name' brand due to the fact that, that's exactly what they are buying. A named brand treatment. Closest example I can think of at the moment (which I know isn't the best example) is your pharmacy brand acetomenaphine vs tylenol. Some people still buy Tylenol, though active ingredient is the same. All just IMO.
News 
Market Data 
Discover 
